• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Special Reports
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Resources
    • About MassDevice
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
    • In-Depth Coverage
    • Latest News
  • Attend DeviceTalks
    • Events
      • DeviceTalks Minnesota – May 4
      • DeviceTalks Boston – May 27–28
      • DeviceTalks West
      • DeviceTalks Tuesdays
    • DeviceTalks Podcast Network
      • DeviceTalks Weekly
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Advertise
  • Subscribe
Home » Cala Health has positive essential tremor treatment data

Cala Health has positive essential tremor treatment data

January 9, 2024 By Sean Whooley

Cala Health kIQ wearable tremor therapy
The kIQ device. [Image from Cala’s website]
Cala today announced results from multiple studies supporting positive outcomes for patients using its TAPS therapy for essential tremor (ET).

San Mateo, California-based Cala develops multiple devices for treating essential tremor, including the Cala Trio and the kIQ. The company launched the kIQ wrist-worn device last year. They deliver transcutaneous afferent patterned stimulation (TAPS) therapy for treating tremor.

One randomized, pragmatic CVS Health trial found that adding Cala TAPS therapy to standard of care improved outcomes over standard of care alone. The study recruited patients from the database of health insurer AETNA. The company says it marks the largest prospective device study run in essential tremor to date, with 310 subjects.

According to a news release, the study found significant improvements in tremor power and Bain & Findley Activities of Daily Living (BF-ADL) upper limb scores over one month of TAPS. It demonstrated TAPS as a safe and effective treatment option for patients with ET.

Other data from Cala

Cala also reported real-world evidence demonstrating consistent relief over multiple years of use for TAPS therapy. It looked at usage data and effectiveness data from 1,223 and 808 subjects, respectively. Data showed effective tremor reduction at a 64% average. It also showed consistent usage with no significant habituation over long-term use (up to 3.4 years).

A secondary analysis looked at TAPS response in patients with high unmet need and those who benefitted from TAPS during their first month of use. It found a significant improvement over the sham in the high unmet need subgroup. The analysis also saw significant improvements over multiple months in the high unmet need group.

“We are excited about the growing body of evidence demonstrating that TAPS improves patient outcomes in real-world settings,” said Kate Rosenbluth, co-president and chief scientific officer, Cala Health. “With these latest publications, TAPS has now been assessed in nearly 2,000 ET patients and with use extending beyond 3 years. TAPS addresses the large treatment gap between medications and surgery for ET patients struggling with activities of daily living such as eating, drinking writing and self-care.”

Filed Under: Clinical Trials, Health Technology, Neurological, Neuromodulation/Neurostimulation Tagged With: Cala Health

More recent news

  • Siemens Healthineers debuts Accela single-breath radiotherapy system
  • GE HealthCare hires chief AI officer from Medtronic
  • Former Teleflex CEO to lead Inspire competitor Nyxoah
  • Retired Stryker leader Tim Scannell dies at 62
  • HighLife raises more than $90M to advance its TMVR system

About Sean Whooley

Sean Whooley is a senior editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

Cart

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >
MDO ad
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2026 · Arrowfly LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy